IL6RA Kit ELISA

N° du produit ABIN2042560

Kit ELISA Humain IL6RA, test Colorimetric pour la quantification de Humain IL6RA.

Aperçu rapide pour IL6RA Kit ELISA (ABIN2042560)

Antigène: IL6RA (Interleukin 6 Receptor, alpha (IL6RA))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Gamme de detection: 31.2-2000 pg/mL

Application: ELISA

Détail du produit IL6RA Kit ELISA

Seuil minimal de détection: 31.2 pg/mL

Réactivité croisée (Details): There is no detectable cross-reactivity with other relevant proteins.

Sensibilité: < 10 pg/mL

Ingrédients: 96-well plate pre-coated with anti-IL-6R alpha, Human
Lyophilized recombinant IL-6R alpha, Human standard, 10 ng/tube, 2Ea
Avidin-Biotin-Peroxidase Complex (ABC), 130 µL (1:100 dilution)
Sample diluent buffer, 30 mL
Antibody diluent buffer, 10 mL
ABC diluent buffer, 10 mL
TMB color developing agent, 10 mL
TMB stop solution, 10 mL

Information d'application

Plaque: Pre-coated

Protocole: Sandwich ELISA quantitative detection kit for Human IL-6R alpha in cell culture supernates, serum, plasma (heparin, EDTA, citrate) and urine.IL6R alpha(IL6RA) also known as CD126 or IL6R, is a type I cytokine receptor. The IL6 receptor is a protein complex consisting of a IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. IL6R also denotes the human gene encoding this subunit. Alternatively spliced transcript variants encoding distinct isoforms have been reported. IL6R subunit is also shared by many other cytokines. Interleukin-6 receptor has been shown to interact with Interleukin 6 and Ciliary neurotrophic factor. Ligand binding did not appear to affect IL6R dimerization status. IL6R dimerization occurs both on the cell surface and in solution.

Restrictions: For Research Use only

Stockage

Stock: 4 °C/-20 °C

Détail du antigène

Antigène: IL6RA (Interleukin 6 Receptor, alpha (IL6RA))

Autre désignation: IL-6R alpha

ID gène: 3570

UniProt: A0N0L5

Pathways: Signalistation JAK/STAT, Autophagy, Growth Factor Binding, Cancer Immune Checkpoints